(BUSINESS WIRE)-- For Non-U.S. and Non-U.K. Media
Boehringer Ingelheim and Eli Lilly and Company announced today the initiation of a Phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albuminuria, and urinary albumin-to-creatinine (UACR) ratio 30-3000 mg/g creatinine, in addition to current standard therapy for diabetic nephropathy. The name of the clinical trial is MARLINA™*.
“With linagliptin, no dose adjustment is required even for patients with declining renal function”, said Professor Per-Henrik Groop, Professor of Nephrology, and Chief Physician at the Division of Nephrology, Helsinki University Central Hospital, Helsinki, Finland and Principal Investigator of the MARLINA™ trial. “What is of particular interest is that this study will evaluate the glycaemic efficacy and safety of linagliptin therapy in patients with type 2 diabetes whose kidneys are excreting significant amounts of albumin, a marker of both, kidney damage as well as an overall increased cardiovascular risk.”
The primary endpoint of MARLINA™ is the change from baseline in HbA1c after 24 weeks of treatment. The study is expected to complete in 2014.
“The initiation of this new trial reinforces our ongoing commitment to the field of type 2 diabetes” said Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. “It is important to find more treatment options, especially for those patients who are at risk of renal and cardiovascular disease and who have limited choices of treatment".
The US Food and Drug Administration (FDA), European Medicines Agency (EMA) and other regulatory authorities worldwide approved linagliptin for the treatment of adult patients with Type 2 Diabetes as monotherapy or in combination with metformin, metformin plus sulphonylurea, and as add-on therapy to insulin. In the US, linagliptin is also approved for use in this population with sulphonylurea and with pioglitazone.1 With linagliptin, no dose adjustment is required regardless of declining renal function or hepatic impairment.1,2
* MARLINA™ (efficacy, safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease with LINAgliptin).
~ENDS~
Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/19_march_2013_linagliptin.html
Contacts
Arnd Prilipp
Launch and Established Products CVM
Boehringer Ingelheim GmbH
Email: arnd.prilipp@boehringer-ingelheim.com
Phone: +49 (6132) 77-2091
or
Tammy Hull
Communications Manager
Lilly Diabetes
Email: hullta@lilly.com
Phone: (317) 651-9116
Permalink: http://me-newswire.net/news/7081/en
No comments:
Post a Comment